GSK269962A (GSK, Marietta, PA, USA), a selective ROCK1 inhibitor, exhibited anti-leukemic effects in murine models of acute myeloid leukemia by inducing apoptosis and inhibiting the ROCK1/c-Raf/ERK signaling axis, thereby reducing leukemic infiltration and prolonging survival [130]. Here, ROCK1 is linked to acute myeloid leukemia.